טוען...
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Combination checkpoint blockade (CCB) targeting inhibitory CTLA4 and PD1 receptors holds promise for cancer therapy. Immune-related adverse events (IRAEs) remain a major obstacle for the optimal application of CCB in cancer. Here, we analyzed B cell changes in patients with melanoma following treatm...
שמור ב:
| הוצא לאור ב: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Clinical Investigation
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5785243/ https://ncbi.nlm.nih.gov/pubmed/29309048 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI96798 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|